NCT02348359: A reported trial by Tyrogenex
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02348359 |
|---|---|
| Title | A Randomized, Double-Masked, Placebo-Controlled, Dose- Finding, Non-Inferiority Study of X-82 Plus Prn Intravitreal (Ivt) Anti-VEGF Compared to Prn Ivt Anti-VEGF Monotherapy in Neovascular AMD |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 16, 2015 |
| Completion date | Dec. 12, 2017 |
| Required reporting date | Dec. 12, 2018, midnight |
| Actual reporting date | May 30, 2018 |
| Date last checked at ClinicalTrials.gov | June 3, 2026 |
| Days late | None |